Is Quest Diagnostics (DGX) a risky stock?
As of July 21, 2026, Clavix grades Quest Diagnostics (DGX) B for risk, a composite score of 70 out of 100 on an A+ to F scale, which puts DGX in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind DGX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how DGX scores on each, as of July 21, 2026.
What's moving DGX's risk right now
Company-specific signals Clavix flags behind DGX's current grade, drawn from recent news and filings as of July 21, 2026.
Guidance cuts or consensus estimate reductions signal near-term earnings pressure that typically precedes multiple contraction.
The favorable ruling for DGX reduces legal liability exposure related to its employee benefit plan fiduciary duties and reinforces its process-based defense against ERISA litigati…
What a B grade means
On the Clavix A+ to F scale, DGX's composite of 70 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell DGX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.